Galmed Pharmaceuticals Ltd.

NasdaqCM:GLMD Stock Report

Market Cap: US$4.8m

Galmed Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of GLMD?
Owner TypeNumber of SharesOwnership Percentage
Private Companies10,4990.16%
Individual Insiders202,7913.08%
Institutions396,9836.03%
General Public5,971,11790.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 191.5%.

Top Shareholders

Top 25 shareholders own 9.27% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
2.63%
Heights Capital Management, Inc.
173,333US$126.2k0%0.05%
1.7%
Two Sigma Investments, LP
112,147US$81.6k429%no data
1.57%
Allen Baharaff
103,065US$75.0k179%no data
0.58%
Citadel Advisors LLC
38,177US$27.8k-24.4%no data
0.48%
Two Sigma Advisers, LP
31,491US$22.9k0%no data
0.34%
Yohai Stenzler
22,116US$16.1k252%no data
0.34%
Guy Nehemya
22,116US$16.1k252%no data
0.34%
Doron Cohen
22,083US$16.1k253%no data
0.21%
Two Sigma Securities, LLC
13,602US$9.9k0%no data
0.18%
Jane Street Group, LLC
12,135US$8.8k0%no data
0.17%
Shmuel Nir
11,286US$8.2k257%no data
0.17%
David Sidransky
11,083US$8.1k255%no data
0.17%
XTX Markets Limited
11,048US$8.0k0%no data
0.17%
Amir Poshinski
11,042US$8.0k253%no data
0.16%
G. Yarom Medical Research Ltd
10,269US$7.5k0%no data
0.028%
UBS Asset Management AG
1,814US$1.3k88.4%no data
0.026%
Nomura Investment Management Business Trust
1,701US$1.2k0%no data
0.014%
BNP Paribas Financial Markets SNC
900US$655.00%no data
0.0045%
Morgan Stanley
298US$217.0204%no data
0.0041%
Blackstone Inc.
272US$197.90%no data
0.0035%
Tushia Consulting Engineers Ltd
230US$167.20%no data
0.00026%
TSFG, LLC
17US$12.50%no data
0.00024%
SBI Holdings, Inc.
16US$11.50%no data
0.00021%
Fédération des caisses Desjardins du Québec
14US$10.10%no data
0.00014%
Wells Fargo & Company
9US$6.70%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/22 06:43
End of Day Share Price 2026/04/22 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Galmed Pharmaceuticals Ltd. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Edward NashCanaccord Genuity
François BriseboisCraig-Hallum Capital Group LLC